UK’s CMA Issues £35m In Fines Over Prochlorperazine
Advanz And Alliance Plan To Appeal Against Decision By Competition Watchdog
Executive Summary
Multiple firms have been fined a total of more than £35m by the UK’s competition regulator in connection with an alleged illegal arrangement connected with anti-nausea drug prochlorperazine that led prices to increase by 700%. But Advanz and Alliance have hit back at the decision, revealing plans to appeal.
You may also be interested in...
Three Remain Liable On UK Liothyronine Price Abuse – But Fines Slimmed On Appeal
Advanz Pharma has failed in its appeal against a £40.9m fine imposed by the UK’s Competition and Markets Authority for its historical pricing practices for liothyronine tablets.
Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
Firms Vow To Appeal After CMA’s £260m Hydrocortisone Fines In UK
Firms censured by the UK’s CMA competition regulator over illegal deals that drove up the price of hydrocortisone for around a decade have vowed to appeal against the decision and the imposition of fines totaling more than £260m.